Advances In™ Treating Interstitial Lung Disease With Progressive Lung Disease Phenotype

Released On
June 30, 2019

Expires On
June 30, 2020

Media Type

Completion Time
60 minutes

Primary Care, Allergy & Immunology, Hospitalist, Nutrition, Pathology, Pulmonology, Rheumatology

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians’ Education Resource®, LLC.


This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)
  • Nurses — 1.0 Nursing Contact Hours

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This online educational activity is directed toward immunologists, radiologists, pathologists, primary care physicians, physician assistants, and advanced practice nurses engaged in the care of patients with ILDs.

Program Overview

Idiopathic pulmonary fibrosis (IPF) is considered the classic presentation of the fibrotic interstitial lung diseases (ILDs). Data suggest that there is a large pool of patients with different clinical ILD presentations and diagnoses who develop a progressive fibrosing phenotype over the course of their disease, resulting in significant challenges in therapy and overall management. With the advent of new therapies in the management of ILDs, it is critical that clinicians be educated on all aspects of the disorder, including earlier identification and differentiation of ILDs, treatment guidelines and clinical management, and IPF risk factors and comorbidities.

Benefits of Participating

  • Gain insights into the importance of early diagnosis and early highly efficacious treatment of PF-ILD to improve lung function and quality of life
  • Improve competence regarding the integration of novel therapies into the management of ILD of a progressive phenotype
  • Increase awareness of clinical trial data for emerging therapies to discern the potential clinical impact on patients with ILDs with progressive lung disease phenotype

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Identify key mechanisms underlying the varied forms of ILDs with progressive lung disease phenotype, clinical presentation, and management
  • Assess safety profiles and toxicities of current and emerging therapeutic agents in treatment of ILDs with progressive lung disease phenotype
  • Evaluate the efficacy and safety of emerging therapeutic agents targeting treatment of ILD with progressive lung disease phenotype


Kristin B. Highland, MD, MSCR

Department of Pulmonary and Critical Care Medicine
Respiratory Institute
Cleveland Clinic Foundation
Cleveland, OH

Zulma X. Yunt, MD

Assistant Professor of Medicine
Clinic Director, Interstitial Lung Disease Program
National Jewish Health
Denver, CO

Accreditation Statement

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.

Disclosures of Conflicts of Interest

Kristin B. Highland, MD, MSCR

  • Grant/Research Support: Actelion Pharmaceuticals, Boehringer Ingelheim, Eiger Pharmaceuticals, Genentech, Reata Pharmaceuticals, United Therapeutics
  • Consultant: Boehringer Ingelheim
  • Speakers Bureau: Actelion Pharmaceuticals, Boehringer Ingelheim, Bayer HealthCare, Gilead Sciences, United Therapeutics

Zulma X. Yunt, MD

  • Speakers Bureau: Boehringer Ingelheim, IPF Non-Branded Disease State Talks

The staff of Physicians' Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.

Disclosure of Unlabeled Use

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and

Instructions for Participation and Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, educational content/audio files will be available for your reference.
  • In order to receive a CME/CE certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME/CE certificate upon completion of these steps.

Hardware and Software Requirements

This site is best viewed with an HTML5 compatible browser. You can visit the independent (3rd party) site to determine if you have the latest version of your browser.

Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, and Real Networks Real One Player.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process